Ethris and EIB Sign €30M Financing for Nasal Antiviral

Ethris GmbH, a biotechnology company, has secured €30 million in financing from the European Investment Bank (EIB) under the HERA Invest initiative. This funding will advance the clinical development of a broad-spectrum nasal antiviral, crucial for pandemic preparedness. The EIB's support underlines the EU's commitment to boosting health innovation and ensuring access to cutting-edge medical solutions for citizens.

Read source